ALS Biologics

Executive Summary

ALS Biologics is a preclinical-stage biotechnology company developing biologic treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Founded in 2020 and headquartered in San Francisco, the company focuses on innovative biologics to address the significant unmet need in ALS, a rare and rapidly progressive neurodegenerative disorder. With a lean team of 10-50 employees, ALS Biologics aims to leverage its expertise in biologics to potentially slow or halt disease progression. However, the company is in early stages with no disclosed pipelines, funding, or valuation, indicating a high-risk profile typical of preclinical ventures. Key upcoming milestones include completing IND-enabling studies and securing Series A financing to advance lead candidates toward clinical trials.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Program20% success
• Q2 2027Series A Financing40% success
• Q4 2026Presentation of Preclinical Data at Major Conference30% success